![]() |
ARTICLE TOOLS |
Publication history |
Reprints |
Cite this article as |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
ACCESSIBILITY
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
A Journal on Dermatology and Sexually Transmitted Diseases
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311
REVIEW
Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):95-101
DOI: 10.23736/S0392-0488.17.05794-7
Copyright © 2017 EDIZIONI MINERVA MEDICA
language: English
Atopic dermatitis treatment: what’s new on the horizon?
Fabrizio PANARESE 1, 2, Matteo AURIEMMA 2, Angelo CARBONE 3, Paolo AMERIO 1, 2 ✉
1 CESI Institute, University of Chieti-Pescara, Chieti, Italy; 2 Department of Dermatology, University of Chieti-Pescara, Chieti, Italy; 3 ”L’immacolata” Clinic, University of the Sacred Heart of Rome, Celano, L’Aquila, Italy
Atopic dermatitis (AD) is an inflammatory disorder of the skin characterized by an impaired immune response and skin barrier function. It is very frequent in adult population being present in up to 10% of population. Quality of life is often reduced in AD patients due to disease burden and symptoms like itch. AD is also frequently associated with psychological diseases such as anxiety or depression. Due to its chronic nature and severity of presentation AD often may not respond to topical treatment and requires systemic treatments which can be associated with significant side effects. A Medline search of the last five years with the keywords “Atopic dermatitis” and “treatment” was performed. Moreover a search throughout the clinicaltrial.gov webpage was performed with the keyword AD. Several topical and systemic treatments are being studied in randomized controlled trials or in case series or in pivotal studies. The progression of the insight on AD pathogenesis have made possible to target single molecules responsible for key aspect of the development of this disease. We discuss the various molecules (small anti-inflammatory molecules, monoclonal antibodies against cytokines) that will be hopefully soon available for the treatment of this disease which still carries an important burden of unmet needs for its treatment.
KEY WORDS: Dermatitis, atopic - Therapeutics - Review